Cochrane · systematic review · CD007419
Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis
Virgili, G, Curran, K, Lucenteforte, E, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
37
current version
GRADE rated
37
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 7 · 18.9%Low 14 · 37.8%Moderate 14 · 37.8%High 2 · 5.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 6 versionsSummary of findings: mean change in best‐corrected visual acuity from baseline to 24 months
Population: people with diabetic macular oedema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Aflibercept | no estimate extracted | 3 studies · 641 participants | Moderate Downgraded: imprecision |
Bevacizumab | no estimate extracted | 3 studies · 261 participants | Low Downgraded: imprecision, indirectness |
Brolucizumab | no estimate extracted | 1 study · 154 participants | Low Downgraded: publication bias |
Ranibizumab deferred laser | no estimate extracted | 1 study · 139 participants | Low Downgraded: imprecision |
Ranibizumab prompt laser | no estimate extracted | 3 studies · 287 participants | Very low Downgraded: risk of bias, inconsistency |
Laser | no estimate extracted | 5 studies · 598 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings: mean change in best‐corrected visual acuity from baseline to 12 months
Population: people with diabetic macular oedema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Faricimab (PTI) | no estimate extracted | 1 study · 632 participants | Moderate Downgraded: imprecision |
Aflibercept | no estimate extracted | 5 studies · 1592 participants | Moderate Downgraded: imprecision |
Brolucizumab | no estimate extracted | 1 study · 368 participants | Moderate Downgraded: imprecision |
Conbercept | no estimate extracted | 1 study · 125 participants | Low Downgraded: risk of bias, imprecision |
Bevacizumab | no estimate extracted | 5 studies · 373 participants | Moderate Downgraded: risk of bias |
Ranibizumab deferred laser | no estimate extracted | 1 study · 188 participants | High |
Ranibizumab prompt laser | no estimate extracted | 7 studies · 746 participants | Moderate Downgraded: risk of bias |
Laser | no estimate extracted | 13 studies · 1296 participants | Moderate Downgraded: indirectness |
Summary of findings: gain of three or more ETDRS lines from baseline to 24 months
Population: people with diabetic macular oedema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Aflibercept | no estimate extracted | 2 studies · 487 participants | Moderate Downgraded: imprecision |
Bevacizumab | no estimate extracted | 1 study · 185 participants | Low Downgraded: imprecision |
Ranibizumab prompt laser | no estimate extracted | 2 studies · 170 participants | Very low Downgraded: risk of bias, imprecision |
Ranibizumab deferred laser | no estimate extracted | 1 study · 139 participants | Low Downgraded: imprecision |
Laser | no estimate extracted | 4 studies · 559 participants | High |
Summary of findings: mean change in central retinal thickness from baseline to 24 months
Population: people with diabetic macular oedema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Aflibercept | no estimate extracted | 3 studies · 640 participants | Moderate Downgraded: imprecision |
Brolucizumab | no estimate extracted | 1 study · 154 participants | Moderate Downgraded: imprecision |
Bevacizumab | no estimate extracted | 2 studies · 261 participants | Moderate Downgraded: imprecision |
Ranibizumab deferred laser | no estimate extracted | 1 study · 136 participants | Moderate Downgraded: imprecision |
Ranibizumab prompt laser | no estimate extracted | 1 study · 136 participants | Moderate Downgraded: imprecision |
Laser | no estimate extracted | 4 studies · 563 participants | Moderate Downgraded: imprecision |
Summary of findings: all‐cause mortality at longest available follow‐up
Population: people with diabetic macular oedema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Aflibercept | no estimate extracted | 10 studies · 2644 participants | Very low Downgraded: imprecision, indirectness |
Bevacizumab | no estimate extracted | 4 studies · 305 participants | Low Downgraded: imprecision |
Brolucizumab | no estimate extracted | 1 study · 368 participants | Low Downgraded: imprecision |
Conbercept | no estimate extracted | 1 study · 125 participants | Very low Downgraded: risk of bias, imprecision |
Faricimab | no estimate extracted | 2 studies · 1262 participants | Low Downgraded: imprecision |
Ranibizumab | no estimate extracted | 11 studies · 2065 participants | Low Downgraded: imprecision |
Summary of findings: Antiplatelet Trialists Collaboration arterial thromboembolic events at longest available follow‐up
Population: people with diabetic macular oedema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Aflibercept | no estimate extracted | 10 studies · 2701 participants | Very low Downgraded: imprecision, indirectness |
Bevacizumab | no estimate extracted | 3 studies · 310 participants | Low Downgraded: imprecision |
Brolucizumab | no estimate extracted | 1 study · 369 participants | Low Downgraded: imprecision, indirectness |
Conbercept | no estimate extracted | 1 study · 125 participants | Very low Downgraded: imprecision, indirectness |
Faricimab | no estimate extracted | 2 studies · 1262 participants | Low Downgraded: imprecision, indirectness |
Ranibizumab | no estimate extracted | 11 studies · 1501 participants | Very low Downgraded: imprecision, indirectness |